Европейский союз - мальтийский - EMA (European Medicines Agency)

stada arzneimittel ag - budesonide, micronised - glomerulonephritis, iga - antidiarrheals, intestinali anti-infjammatorji / antiinfective aġenti - kinpeygo is indicated for the treatment of primary immunoglobulin a (iga) nephropathy (igan) in adults at risk of rapid disease progression with a urine protein-to-creatinine ratio (upcr) ≥1. 5 g/gram.

Европейский союз - мальтийский - EMA (European Medicines Agency)

covis pharma europe b.v. - aclidinium bromide - mard tal-pulmun, obstructive kronika - mediċini għall-imblokkar tal-passaġġ tan-nifs mard, - eklira genuair huwa indikat bħala trattament ta 'manteniment tal-bronkodilatur biex itaffi s-sintomi f'pazjenti adulti b'mard pulmonari ostruttiv kroniku (copd).

Европейский союз - мальтийский - EMA (European Medicines Agency)

novartis europharm ltd - glycopyrronium bromide - mard tal-pulmun, obstructive kronika - mediċini għall-imblokkar tal-passaġġ tan-nifs mard, - enurev breezhaler hija indikata bħala trattament bronchodilator manutenzjoni biex jeħles sintomi fil-pazjenti adulti bil-marda pulmonari eliminat kronika (copd).

Европейский союз - мальтийский - EMA (European Medicines Agency)

novartis europharm limited - glycopyrronium bromide - mard tal-pulmun, obstructive kronika - mediċini għall-imblokkar tal-passaġġ tan-nifs mard, - seebri breezhaler huwa indikat bħala trattament ta 'manteniment tal-bronkodilatur biex itaffi s-sintomi f'pazjenti adulti b'mard pulmonari ostruttiv kroniku (copd).

Европейский союз - мальтийский - EMA (European Medicines Agency)

novartis europharm limited - indacaterol, glycopyrronium bromide - mard tal-pulmun, obstructive kronika - adrenerġiċi fil-kombinazzjonijiet ma ' l-antikolinerġiċi inkl. tripla-kombinazzjonijiet ma ' kortikosterojdi - xoterna breezhaler huwa indikat bħala trattament ta 'manteniment tal-bronkodilatur biex itaffi s-sintomi f'pazjenti adulti b'mard pulmonari ostruttiv kroniku (copd).

Европейский союз - мальтийский - EMA (European Medicines Agency)

bausch health ireland limited - methylnaltrexone bromide - opioid-related disorders; constipation - periferali tal-opioid ta ' l-antagonisti tar-riċettur - trattament ta 'stitikezza li tittieħed mill-opjojdi f'pazjenti b'mard avvanzat li qed jirċievu kura palljattiva meta r-rispons għat-terapija laxattiva normali ma kienx biżżejjed.

Европейский союз - мальтийский - EMA (European Medicines Agency)

novartis europharm limited - indacaterol, glycopyrronium bromide - mard tal-pulmun, obstructive kronika - adrenerġiċi fil-kombinazzjonijiet ma ' l-antikolinerġiċi inkl. tripla-kombinazzjonijiet ma ' kortikosterojdi, mediċini għall-imblokkar tal-passaġġ tan-nifs mard, - ultibro breezhaler huwa indikat bħala trattament ta 'manteniment tal-bronkodilatur biex itaffi s-sintomi f'pazjenti adulti b'mard pulmonari ostruttiv kroniku (copd).

Европейский союз - мальтийский - EMA (European Medicines Agency)

novartis europharm limited - glycopyrronium bromide, indacaterol maleate - mard tal-pulmun, obstructive kronika - mediċini għall-imblokkar tal-passaġġ tan-nifs mard, - ulunar breezhaler huwa indikat bħala trattament tal-bronkodilatur tal-manteniment biex itaffi s-sintomi f'pazjenti adulti b'mard pulmonari ostruttiv kroniku (copd).

Европейский союз - мальтийский - EMA (European Medicines Agency)

novartis europharm limited - glycopyrronium bromide - mard tal-pulmun, obstructive kronika - mediċini għall-imblokkar tal-passaġġ tan-nifs mard, - tovanor breezhaler huwa indikat bħala trattament ta 'manteniment tal-bronkodilatur biex itaffi s-sintomi f'pazjenti adulti b'mard pulmonari ostruttiv kroniku (copd).

Европейский союз - мальтийский - EMA (European Medicines Agency)

chiesi farmaceutici s.p.a. - beclometasone dipropionate, formoterol fumarate dihydrate, glycopyrronium bromide - mard tal-pulmun, obstructive kronika - mediċini għall-imblokkar tal-passaġġ tan-nifs mard, - maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and high dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year. copdmaintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist or a combination of a long-acting beta2-agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5. asthmamaintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and medium dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year.